Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530301 | 1.00 | ALDH1A1 (0.77) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL1849659 | 1.00 | ALDH1A1 (0.77) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4676912 | 0.98 | ALDH1A1 (0.80) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6993232 | 0.98 | ALDH1A1 (0.80) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL30995662 | 0.91 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL725878 | 0.89 | ALDH1A1 (0.72) | ALDH1A1CYP1A2CYP2D6KMT2AANPEP | |
| SCHEMBL15087836 | 0.89 | ALDH1A1 (0.97) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL15090295 | 0.89 | ALDH1A1 (0.97) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL6262911 | 0.86 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2D6KMT2ADNM1 | |
| SCHEMBL15325585 | 0.85 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025098445-A1 | PARG INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | 南京同诺康医药科技有限公司 | 2025-05-15 | — | — | WO | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024173514-A1 | AMIDE AND ESTER-SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS | IDEAYA BIOSCIENCES, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-9663506-B2 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9636337-B2 | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2016119707-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016119707-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-08-04 | — | — | WO | disclosed |
| US-20160158217-A1 | Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159744-A1 | Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | US | disclosed |
| US-7196091-B2 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-27 | — | — | US | disclosed |
| US-20060264450-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HIMMELSBACH FRANK | 2006-11-23 | — | — | US | disclosed |
| EP-1641767-A2 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PREPARING THE SAME | Boehringer Ingelheim International GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108664-A2 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PREPARING THE SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-16 | — | — | WO | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, CYP11B1, CYP11B2 | ALDH1A1 1923/4885CYP1A2 633/4885CYP2D6 1219/4885 |
| US-20060264450-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, CYP11B1, CYP11B2 | ALDH1A1 1923/4885CYP1A2 633/4885CYP2D6 1219/4885 |
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | ALDH1A1 4/4885CYP1A2 14/4885CYP2D6 42/4885 |
| US-20160159744-A1 | Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use | GRIN2A, GRIA2, GRIN2B | ALDH1A1 4241/4885CYP1A2 858/4885CYP2D6 2310/4885 |
| US-20160158217-A1 | Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use | GRIN2A, GRIA2, GRIN2B | ALDH1A1 4241/4885CYP1A2 858/4885CYP2D6 2310/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | ALDH1A1 4/4885CYP1A2 14/4885CYP2D6 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.